Budoprutug clinical trials
Budoprutug is named as an intervention in 4 current clinical trials in our USA, China, Spain, Brazil and Taiwan registers. 4 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Climb Bio, Inc. The most-studied condition is Primary Membranous Nephropathy.
How Budoprutug works
All drug targets →- Focal segmental glomerulosclerosisPhase 2
- Minimal change diseasePhase 2
- Autoimmune thrombocytopenic purpuraPhase 1/2
- Membranous glomerulonephritisPhase 1/2
- Systemic lupus erythematosusPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314814, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Budoprutug
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Budoprutug
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843 · Primary Membranous Nephropathy
|
Phase 2 | Recruiting | Climb Bio, Inc | USA, China, Brazil, Taiwan |
|
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
NCT07043946 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP), ITP, Biologics
|
Phase 1/2 | Recruiting | Climb Bio, Inc | Spain |
|
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596 · ClinicalTrials.gov ↗ · Systemic Lupus Erthematosus
|
Phase 1/2 | Recruiting | Climb Bio, Inc | China |
|
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043 · Systemic Lupus Erythematosus
|
Phase 1 | Recruiting | Climb Bio, Inc | USA, Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Budoprutug
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Climb Bio, Inc | 4 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in China | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Brazil | 1 | 1 |
| Clinical trials in Taiwan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Budoprutug trials
How many clinical trials are testing Budoprutug?
4 current trials in our USA, China, Spain, Brazil and Taiwan registers name Budoprutug (also registered as TNT119) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Budoprutug trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 2 with sites in USA, 2 with sites in China, 2 with sites in Spain, 1 with sites in Brazil and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Budoprutug clinical trials?
The lead sponsor is Climb Bio, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Budoprutug works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Budoprutug works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Budoprutug (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.